Improving Patient Adherence and Quality of Life in ALS: New Insights on Optimizing Adverse Event Management and Patient Health Maintenance

A continuing medical education activity sponsored by NAMCP and AAMCN.

New Horizons in the Management of ALS: Leveraging Emerging Therapeutic Breakthroughs to Make Informed Decisions is a 3-part live webinar series that will provide attendees with
the latest information in the management of ALS

This is Part 1 of the series focusing on patient health maintenance in ALS

This activity is an archive from the webinar held January 15, 2020

This activity is valid from February 1, 2020 to February 1, 2022

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Biogen and Mitsubishi Tanabe Pharma America

Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. An estimated 20,000 people in the US are living with ALS. Although most patients with ALS die within 3 to 5 years after symptoms first appear, about 20% of patients with ALS will live 5 years, 10% will live 10 years, and about 5% will live 20 years or more. Currently, there is no cure for ALS, but fortunately, the treatment paradigm has expanded in recent years, giving healthcare professionals many more options in managing symptoms and delaying progression.

Upon completion of this activity, participants will be able to:

  • Implement effective strategies to improve medication management and patient health maintenance

  • Identify and overcome the current challenges of providers and payers in relation to ALS treatment access

  • Explore strategies to monitor and manage adverse events associated with available and emerging treatments in ALS in order to improve patient adherence and quality of life

  • Optimize the management of symptoms associated with ALS with novel treatment strategies

Faculty: Richard Bedlack, MD, PhD
Professor of Neurology
ALS Clinic Director
Duke University


Dr. Bedlack has served as a consultant for the ALS Association, Biohaven, Biogen, Brainstorm, ITF Pharma, Mallinkrodt, MT Pharma, New Biotic, and Woolsey Pharma. He has received grants/research support from the ALS Association, Cytokinetics, Orion, and Ultragenyx. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Biogen and Mitsubishi Tanabe Pharma America

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue